BIO Should Use Political Clout Carefully, Outgoing President Feldbaum Urges
The biotechnology industry should reserve its political influence for the most fundamental policy issues, outgoing Biotechnology Industry Organization President Carl Feldbaum told the association's annual meeting in San Francisco June 8
You may also be interested in...
The Biotechnology Industry Organization will begin the process of selecting a new president at its Feb. 23 board meeting in New York
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials